Views
Published by

Human Health's Trading

Published on 22 December 2012, by M. Tomazy.
There is almost no reliable reports on pharmaceutical companies, especially by investigative journalists.
The process of drug manufacturing is kind of  corruption by itself, other than the hidden medical hazards for the 'new product' and suspected corrupted deals.

Initially, engaging the human's health status directly with trading companies is kind of corruption, so how can the commercial company care about the health of poor people?
 No wonder because this is one manifestation of Capitalism, but what about the right of poor people to be equally treated like rich.

The ill 'customer' should pay (per box) for the researcher (in form of patent fees), and for the company's employee, and for  profits which might be officially registered in Stock markets, likely Wall street and Frankfurt.
On other hand, many Pharmaceutical companies are accused of hiding some serious adverse which could be lethal or teratogenic.

For instance, Thalidomide was a drug, which after years of extensive animal tests, was first marketed as an over-the-counter sedative: it came to be used by pregnant women in many countries during the late 1950s and early 1960s as a treatment for morning sickness.

This year, the German manufacturing company has officially admitted Thalidomide catastrophic side effect in form of teratogenic effect (i.e,  many babies were born with no limbs or deformed one or more limbs), whereas it was introduced to the 'market' in 1950s.
  Other children also received Thalidomide in the same high dosage. One child had a circulatory collapse, one died from a congenital heart defect, a three-month-old baby died from heart failure, a twentyone-month-old baby temporarily lost her vision. The doctor responsible stopped using the drug when he heard that his medical colleagues had similar experiences with Thalidomide (Although twelve years would elapse before Thalidomide was withdrawn from the market).
 In 1955, one year before the commencement of the marketing of Thalidomide in its various formulae, three physicians, along with a Professor Kloos, took part in a symposium arranged by Chemie GrĂ¼nenthal at which they reported to the company unsatisfactory experiences with Thalidomide. However, these were ignored”.

Few years ago, World Health Organization (WHO) warned of new influenza virus outbreaks causes Avian Flu (Birds Flu), thereafter, another viral outbreaks cause (Swine Flu) has been appeared.
Pharmaceutical companies found it an opportunity for 'doubling profits', and so they engaged a commercial competition to introduce their new 'product'  which is the vaccination in a different 'shapes' and techniques.



The vaccine manufacturing company Novartis has recently made the news this time with the recall of 160,000 dosages of the Aggripal influenza flu vaccination in both the United Kingdom and Italy. The recall was due to ‘particles seen floating in the vials’ the particles were later determined to be protein aggregates. When researching protein aggregates we soon find that they are not only dangers misfolded proteins but they are also toxic and linked to amyloidal diseases such as Alzheimer’s, Parkinson’s and Pion’s. These 160,000 doses of Aggripal were so saturated with protein aggregates that they were visible to the naked eye as floating particulate matter.